Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pathol Res Pract ; 210(12): 818-21, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25282546

ABSTRACT

INTRODUCTION: Lymph node (LN) assessment after colorectal cancer resection is fundamentally important for therapeutic and prognostic reasons. LN positivity is an indication for adjuvant treatment. This study aimed to investigate whether immediate postoperative intra-arterial methylene blue (MB) injection (MBI) into colorectal cancer specimens by a surgeon in the operating room could improve the rate of total LN and metastatic LN recovery for pathological examination. MATERIALS AND METHODS: Seventy-three consecutive patients prospectively enrolled between January 2011 and December 2013 were assigned to the methylene blue (MB)-stained group and compared with 107 controls in the unstained group. RESULTS: The median number and range values of metastatic LNs, the number of LNs <0.5 cm, the total number of LNs harvested, and the number of cases with LN metastasis were significantly different between the MB-stained and MB-unstained groups (p = 0.016, p = 0.010, p = 0.025, and p = 0.006 respectively). CONCLUSIONS: Immediate MBI (fresh, unfixed samples) by a surgeon in the operating room may result in a significant increase in the number of metastatic LNs diagnosed and the number of cases with positive LNs. Shifting of the injection from the pathology laboratory to the operation theater would be a good alternative whenever the operation theater is not the area located as the pathology department.


Subject(s)
Adenocarcinoma/secondary , Colorectal Neoplasms/pathology , Coloring Agents , Lymph Nodes/pathology , Methylene Blue , Operating Rooms , Adenocarcinoma/surgery , Case-Control Studies , Colectomy , Colorectal Neoplasms/surgery , Coloring Agents/administration & dosage , Female , Humans , Injections, Intra-Arterial , Lymph Nodes/surgery , Lymphatic Metastasis , Male , Methylene Blue/administration & dosage , Middle Aged , Neoplasm Staging , Predictive Value of Tests , Prospective Studies , Workflow
2.
Pathol Res Pract ; 210(10): 640-4, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25042388

ABSTRACT

With the revision of the Gleason system at the 2005 International Society of Urological Pathology Consensus Conference, there was consensus that most cribriform glands should be classified as pattern 4. There is now increased understanding that invasive cribriform carcinoma is a relatively aggressive disease. This study was based on 233 radical prostatectomy (RP) specimens collected at the Department of Pathology, Umraniye Education and Research Hospital, from 2006 to 2013. We assessed the cribriform foci associated with the more definitive patterns 3, 4, and 5 elsewhere on the RP specimens and evaluated the association of the presence of cribriform pattern (CP) with biochemical prostate-specific antigen recurrence (BPR). In Cox regression model, taking into account the Gleason score (GS), pathologic stage, surgical margin (SM) status, presence of a CP, and preoperative prostate-specific antigen (PSA), a positive SM, and the presence of a CP were independent predictors of BPR after RP. We observed BPR more frequently in GS 3+3 cases with a CP than in those without a CP (p=0.008). There was no significant difference in BPR status for cases with GS 3+4, 4+3, 4+5, and 5+4 when the patients were stratified by the presence of a CP. On the basis of these data, we suggest that the classification of CP into Gleason pattern 4 has value in predicting BPR status after RP. However, as many of these modifications are empirical and supported by only a few studies, long-term follow-up studies with clinical endpoints are necessary to validate these recommendations.


Subject(s)
Adenocarcinoma/pathology , Prostate-Specific Antigen/metabolism , Prostatic Neoplasms/pathology , Humans , Male , Neoplasm Grading/methods , Neoplasm Recurrence, Local/pathology , Prognosis , Prostatectomy/methods , Prostatic Neoplasms/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...